This assignment investigates the use of BAN2401 (Aβ mAb) in the treatment of Alzheimer's disease. The introduction provides background on Alzheimer's disease, its prevalence, symptoms, and current treatments, highlighting the role of amyloid plaques and tangles. The study proposes a six-arm clinical trial design involving 50 participants over 12 months, utilizing various dosages of BAN2401. The methods section details participant selection criteria, including age and MMSE scores, and outlines the procedures, including blood tests, MMSE assessments, and imaging. The primary outcome measure is assessed using the ADCOMS test every three months, while secondary outcomes include CDR global range and MMSE. Data analysis involves longitudinal Bayesian analysis and repeated ANOVA tests. The conclusion emphasizes the need for new treatments and the potential of BAN2401 to improve the lives of those affected by Alzheimer's disease, discussing the drug's mechanism of action and advantages.